Anixa Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $123.8M
- Price
- $3.71
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.34%
- Volume
- 182.6K
About
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
Quick stats
Shares outstanding33.4M
Computed float22.2M
Float / shares66.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000715446
Websitehttps://www.anixa.com
AI Summary
AI-generated1/20
standardbullishclinical trial
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Anixa Biosciences announced management will present at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting clinical progress in its oncology pipeline.
The company's ovarian cancer CAR-T therapy, lira-cel, has advanced to the fifth and highest dose cohort incorporating lymphodepletion, showing no dose-limiting toxicities and achieving survival of over one year in four patients, with the longest at approximately 28 months.
Additionally, the breast cancer vaccine Phase 1 trial met all primary endpoints with protocol-defined immune responses in 74% of participants, and preparations for a Phase 2 trial are underway.